Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

15-valent pneumococcal conjugate vaccine · PCV15

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides · developed by Merck Sharp & Dohme LLC

Phase 2 Most advanced trial

What is 15-valent pneumococcal conjugate vaccine?

15-valent pneumococcal conjugate vaccine (PCV15) is a vaccine against Streptococcus pneumoniae. It is studied in pneumococcal disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PCV15
Drug type
Vaccine (Recombinant protein vaccine)
Targets
Streptococcus pneumoniae capsular polysaccharides (antigen)
Mechanism
Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides
Therapy area
Infectious disease
Developer
Merck Sharp & Dohme LLC
In trials of
PFE
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

Conditions studied

Pneumococcal Disease

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.